Clinical Evaluation of the Safety and Performance of 
Fractional Radiofrequency for the Treatment and 
Reduction of Facial Wrinkles  
Protocol Identifying Number:  VI1218 
Principal Investigator:   [INVESTIGATOR_124]. Neil Sadick 
Funded by: [CONTACT_520340]: 1.[ADDRESS_674927] Toronto, ON  M2J 1R4 Tel. 888‐907‐0115  
Email: [EMAIL_3066]  
 
 
______________________________                       ___________________ 
  Signature [CONTACT_520349]:  (DD/MMM/YYYY) 
10/09/18
ii 
 Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1 
PROTOCOL SUMMARY  ........................................................................................................................................... 3 
SCHEMATIC OF  STUDY DESIGN  .......................................................................................................................... 4 
1 KEY ROLES  .................................................................................................................................................... 4 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................ 5 
2.1 Background Information  ...................................................................................................................... 5 
2.2 Rationale  ............................................................................................................................................... 5 
2.3 Potential Risks and Benefits  .............................................................................................................. 6 
2.3.1  Known Potential Risks  ..................................................................................................... 6 
2.3.2  Known Potential Benefits  ................................................................................................ 6 
3 OBJECTIVES AND PURPOSE  .................................................................................................................... 6 
4 STUDY DESIGN AND ENDPOINTS  ........................................................................................................... 7 
4.1 Description of the Study Design  ........................................................................................................ 7 
4.2.1  Primary Endpoint  .............................................................................................................. 7 
4.2.2  Secondary Performance Endpoints  ............................................................................... 7 
4.2.3  Safety Endpoints  .............................................................................................................. 7 
5 STUDY ENROLLMENT AND WITHDRAWAL  ........................................................................................... 7 
5.1 STUDY POPULATION  ........................................................................................................................ 7 
5.2 Participant Inclusion Criteria .............................................................................................................. 7 
5.3 Participant Exclusion Criteria ............................................................................................................. 7 
5.4 Strategies for Recruitment and Retention  ........................................................................................ 8 
5.5 Participant Withdrawal or termination  ............................................................................................... 8 
5.5.1  Reasons for Withdrawal or Termination  ....................................................................... 8 
5.5.2  Handling of Participant Withdrawals or termination  .................................................... 9 
5.6 Premature Termination or Suspension of Study  ............................................................................. 9 
6 INVESTIGATIONAL DEVICE  ..................................................................................................................... 10 
6.1 Investigational device and Control Description  ............................................................................. 10 
6.1.1  Acquisition  ....................................................................................................................... 10 
6.1.2  Device Specific Considerations  ................................................................................... 10 
6.2 Investigational device Accountability Procedures  ......................................................................... 11 
7 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 11 
7.1 Study Procedures/Evaluations  ......................................................................................................... 11 
7.1.1  Study specific procedures  ............................................................................................. 11 
7.2 Laboratory Procedures/Evaluations  ................................................................................................ 11 
7.2.1  Clinical Laboratory Evaluations  .................................................................................... 11 
7.2.2  Other Assays or Procedures  ........................................................................................ 11 
7.3 Study Schedule  .................................................................................................................................. 12 
7.3.1  Enro llment/Screening  .................................................................................................... 12 
7.3.2  Baseline Visit  .................................................................................................................. 13 
7.3.3  Treatment Visits  ............................................................................................................. 13 
7.3.4  Follow Up Visits  .............................................................................................................. 15 
7.3.5  Early Termination Visit  .................................................................................................. 16 
7.3.6  UNSCHEDULED Visit  ................................................................................................... 16 
7.3.7  Schedule of Events Table  ............................................................................................. 17 
7.4 Justification for Sensitive Procedures  ............................................................................................. 17 
iii 
 7.5 Concomitant Medications, Treatments, and Procedures  ............................................................. 17 
7.6 Prohibited Medications, Treatments, and Procedures  .................................................................  17 
7.7 Prophylactic Medications, Treatments, and Procedures  ............................................................. 18 
7.8 Rescue Medications, Treatments, and Procedures  ..................................................................... 18 
8 ASSESSMENT OF SAFETY  ...................................................................................................................... 18 
8.1 Specification of Safety Parameters  .................................................................................................  18 
8.1.1  Definition of Adverse Events (AE) and adverse device effect (ADE)  ..................... 18 
8.1.2  Definition of Serious Adverse Events ( SAE)  .............................................................. [ADDRESS_674928] (SADE)  .................................................. 19 
8.1.4  Definition of Device deficiency  ..................................................................................... 19 
8.2 Classification of an Adverse Event  .................................................................................................  19 
8.2.1  Severity of Event  ............................................................................................................ 19 
8.2.2  Relationship to INVESTIGATIONAL DEVICE  ........................................................... 20 
8.2.3  Expectedness  ................................................................................................................. 21 
8.3 Time Period and Frequency for Event Assessment and Follow -Up .......................................... 21 
8.4 Reporting Procedures  ....................................................................................................................... 22 
8.4.1  Adverse Event Reporting  .............................................................................................. 22 
8.4.2  Serious Adverse Event Reporting  ............................................................................... 22 
8.4.4  Reporting of Pregnancy  ................................................................................................ 23 
8.5 Study Halting Rules  ........................................................................................................................... 23 
8.6 Safety Oversight  ................................................................................................................................ 23 
8.7 Training Requirements  ...................................................................................................................... 23 
9 CLINICAL MONITORING ............................................................................................................................ 23 
10 STATISTICAL CONSIDERATIONS .......................................................................................................... 24 
10.1  Statistical and Analytical Plans  ........................................................................................................ 24 
10.2  Statistical Hypotheses  ....................................................................................................................... 24 
10.3  Analysis Datasets  .............................................................................................................................. 25 
10.4  Description of Statistical Methods  ................................................................................................... 25 
10.4.1  General Approach  .......................................................................................................... 25 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 25 
10.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 26 
10.4.4  Safety Analyses  .............................................................................................................. 27 
10.4.5  Adherence and Retention Analyses  ............................................................................ 27 
10.4.6  Baseline Descriptive Statistics  ..................................................................................... 28 
10.4.7  Planned Interim Analyses  ............................................................................................. 28 
10.4.9  Multiple Comparison/Multiplicity ................................................................................... 28 
10.4.10  Tabulation of Individual Response Data  ..................................................................... 28 
10.4.11  Exploratory Analyses  ..................................................................................................... 28 
10.5  Sample Size  ....................................................................................................................................... 28 
10.6  Measures to Minimize Bias  .............................................................................................................. 29 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 29 
10.6.2  Evaluation of Success of Blinding  ............................................................................... 29 
10.6.3  Breaking the Study Blind/Participant Code  ................................................................ 29 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 30 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 30 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_674929]  .................................................................................................................................  31 
13.2  Ethics committee and competent authorities  ................................................................................. 31 
13.3  Informed Consent Process  ............................................................................................................... 31 
13.3.1  Consent/assent and Other Informational Documents Provided to Participants .... [ADDRESS_674930] OF ABBREVIATIONS  ..................................................................................................................................... 36 
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674931] version of the Declaration of Helsinki 
(2013), ISO [ZIP_CODE] :2011  (Clinical investigation of medical devices for human subjects -  Good clinical 
practice ), Medical Devices Directive 93/42/EEC, MEDDEV 2.7/3, [LOCATION_002] (US) Code of Federal 
Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  and any of the applicable regional or national regulation s pertaining to 
conduct of a clinical investigation of a medical device.  
The clinical investigation shall not begin until the required approval or favorable opi[INVESTIGATOR_10363] ( EC) has been obtained and, if applicable, any local or national regulatory authority approvals 
or notifications have been obtained.  
Any additional requirements imposed by [CONTACT_484524].  
The Sponsor has obtained clinical investigation insurance that will cover expenses in the event of any physical injury resulting from research procedures.  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  3  
PROTOCOL SUMMARY  
 
TITLE  Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency  
for the Treatment and Reduction of Facial Wrinkles   
SUMMARY  Prospective,  single centre , evaluator -blind study of the safety and performance 
of fractional radiofrequency ( RF) for the treatment and reduction of facial 
wrinkles .  The s tudy will  evaluate [ADDRESS_674932] one treatment. An additional histological analysis 
will be conducted including up to 12 of the participating subjects.  
OBJECTIVES  The objective of this clinical study is to evaluate the safety and performance of 
fractional RF for the treatment and reduction of facial wrinkles . 
ENDPOINT  Primary performance endpoints  
• Improvement  in facial wrinkles  at [ADDRESS_674933] -
treatm ent compared  to baseline  as assessed  by [CONTACT_519801]  (FWES)  scale.   
 
Secondary performance endpoints  
• Subjects’ assessment of satisfaction with the treatment using a Subj ect  
Satisfaction Scale at [ADDRESS_674934] -treatment.  
• Report histological changes in a treated area at baseline, immediately 
post -treatment,  [ADDRESS_674935] treatment.  
 
Safety endpoints  
• Subject’s assessment of discomfort and pain after treatments as 
measured by a 10 cm visual analog scale (VAS)  and Tolerability Scale  
• Subjects experiencing a treatment- related adverse event ( AE) by [ADDRESS_674936] -Market  
NUMBER OF SITES  1  
DESCRIPTION OF 
DEVICE  The Venus Viva™ fractional RF device has been shown in clinical studies to 
improve various skin conditions related to aging and alter collagen structures 
such as wrinkles, rhytids  and scars .  The device offers the option of 80 and 160 
pin tips, to deliver nano fractional RF energy to the treatment  site. 
STUDY DURATION  Approximately 8 months  
PARTICIPANT 
DURATION  6 months  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  4  
SCHEMATIC OF STUDY D ESIGN  
 
Screening  Visit  
 Obtain Informed Consent , Screen Potential Subjects By [CONTACT_520341];  Medical History, Administer Test Spot, Physical Exam,  
Demographics  
  
Visit 1 – 
Baseline /Tx [ADDRESS_674937] Spot, Confirm Eligibility status, AEs, Concomitant Medication, 
Photographs ,  Administer Initial Study Treatment, 10 cm Pain VAS  and 
Tolerability Scale , Baseline Histology and Immediate/Post -Treatment Histology  
  
Histology visit a 
Week1  (+/- 1 
week)  Histology, AEs, Concomitant Medication  
  
Visit 2 -Tx2 
Week 4   
(+/- 1 week ) AEs, Concomitant Medication , Administer Study Treatment,  
10 cm Pain VAS  and Tolerability Scale  
  
Visit 3 -Tx3 
Week 8  
(+/- 1 week )  AEs, Concomitant Medication , Administer Study Treatment,  
10 cm Pain VAS  and Tolerability Scale  
  
Visit 4 – FU1 
[ADDRESS_674938] - final 
treatment  
(+/- 1 week)  AEs, Concomitant Medication, Photographs, Subject  Satisfaction Scale , 
Treatment Evaluation Questionnaire,  
  
Visit  [ADDRESS_674939] -
final treatment  
(+/- 1 week)  AEs, Concomitant Medication, Photographs,  Subject  Satisfaction Scale , 
Treatment Evaluation Questionnaire,  Histology  
 a For subjects  selected for histology analysis only  
 
[ADDRESS_674940] , Suite 1A  | [LOCATION_001], NY [ZIP_CODE]  
Tel. (212) 772- 7242 
Email: [EMAIL_9951]  
 
Paul Cardarelli  
Senior Director of Product Marketing and Clinical Affairs  
Venus Concept  
[ADDRESS_674941]  
Toronto, Ontario, M2J 1R4  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  5 CANADA  
Tel. 888 -907-0115  
Email: pcardarelli @venusconcept.com  
 
 
 
2  INTRODUCTION: BAC KGROUND INFORMATION AND SCIENTIFIC RATIO NALE   
 
2.[ADDRESS_674942] acne scars, and facial wrinkles, clinically referred  to 
as rhytides, are common skin conditions in both men and women. The appearance of these types of 
facial irregularities  can result in distress for  people of all ages, causing them to turn to cosmetic 
treatments such as surgical procedures (e.g., face lifts) as well as non -surgical procedures including 
chemical or laser peels, non -ablative laser resurfacing, or dermabrasion. These procedures are usually 
associated with prolonged recovery times as well as arduous side effects. To circumvent these issues, the use of non -invasive, nonsurgical approaches that do not require downtime are becoming the 
preferred method of choice for patients seeking  cosmetic  improvements.  An innovative technique that 
was introduced to reduce facial wrinkles and rhytides is known as radiofrequency (RF)
4. 
The premise behind RF technology is dermal heating, which initiates the denaturation of collagen and 
the stimulation of neo collagenesis through the  induction of inflammation that leads to the production of 
fibroblasts at the heated area and the subsequent development of new collagen.3,4 RF energy produces 
an oscillating electrical current that can penetrate the dermis and hypo dermal tissues without disturbing 
the epi[INVESTIGATOR_3915] -dermal barrier. The generation of the heat energy is the result of the natural resistance 
that dermal tissue has to the movement of ions with an electromagnetic field. Accordingly, the 
oscillating electrical current causes collisions between charged ions that are transformed into heat 
energy.3,5 The heat produced in  nonablative skin rejuvenation with RF -based systems  typi[INVESTIGATOR_520335]
4 
RF techniques that improve the ability to control the ablation and coagulation of the skin can result in treatment consistency that will provide more flexibility to treat a wider variety of skin conditions.  In 
fractional resurfacing, thermally ablated microscopic zones  of epi[INVESTIGATOR_10365] a grid 
over the skin surface;  the nonablated zones in the uninjured surrounding tissue  serves as a reservoir of 
cells promot ing safe and rapid healing
1.  Fractional RF treatment has been demonstrated to be a safe, 
tolerable  and effective choice to reduc e wrinkles an d provide an  overall improvement in skin texture1,4. 
 
2.[ADDRESS_674943] -treatment changes in skin morphology . 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  6 The use of the Venus Viva ™ has been determined to present non -significant risk in accordance with  21 
CFR 812.3 for the intended use in this study, because the device is not:  
• Intended as an implant;  
• Purported or represented to be for use supporting or sustaining human life;  
• Substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
• Otherwise present ing a potential for serious risk to the health, safety, or welfare of a subject.  
This study will be conducted in compliance with the protocol and according to Go od Clinical Practice 
(GCP) standards.  
2.[ADDRESS_674944] -treatment, e xcessive skin redness (erythem a) and/or swelling 
(edema) , in-grown hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] 
(hyper - and hypo -pi[INVESTIGATOR_371])  and scarring . Treatment of hair- bearing areas in male patients may 
result in some damage to the follicl es and subsequent loss of hair.  Avoid the beard area and other hair-  
growing zones if the patient does not wish to experience hair growth reduction.   For the punch biopsy, 
there is a very minimal risk of infection or bleeding.  
Further information about re sidual risks associated with the device  and with participation  in the clinical 
investigation are reported in the device User Manual . 
Residual risks will be mitigated as follows:  
− Selection of an investigator with experience in the therapeutic area of the clinical investigation  
− Investigator and site staff will have already undergo ne training prior to patients’ enrollment  
− Prior to  the first procedure, the investigator and site staff will undergo a re -training session by 
[CONTACT_484528]  
− Patients will be rigorously screened prior to their enrollment  
− Patients will be rigorously followed over the course of the study  
 
2.3.[ADDRESS_674945] agrees to participate in this study, he/ she will be contributing to the understanding of the 
device’s impact and the biological processes that are occurring regarding wrinkle formation . This 
understanding may lead to optimization of the treatment with this device  for these indications .  In 
addition,  the subject may benefit from improvement in facial wrinkle  appearance in the treated area s. 
3 OBJECTIVES AND  PURPOSE  
This clinical study is being conducted  to evaluate the safety and performance of nano fractional RF for 
the treatment and reduction of facial wrinkles.  Total expected duration of the clinical investigation  is 
eight months  (enrolment period of 2 months, follow -up period of 6  months ), while individual subject 
participation will take  approximately  6 months.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  7 4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF T HE STUDY DESIGN  
This is a  prospective, evaluator- blind study of the safety and performance of fractional RF for the 
treatment  and reduction  of facial wrinkles.  
4.2.1 PRIMARY ENDPOINT  
• Improvement in facial wrinkles at [ADDRESS_674946] -intervention compared to 
baseline as assessed by [CONTACT_10387] (FWES)  scale.  
4.2.2 SECONDARY PERFORMANCE ENDPOINTS  
 
• Subjects’ assessment of satisfaction with  the treatment using the Subject  Satisfaction Scale  at [ADDRESS_674947]- treatment.  
• Report histological changes in a treated area at baseline, immediately post -treatment, [ADDRESS_674948] treatment.  
4.2.3  SAFETY ENDPOINTS  
• Subjects ’ assessment of discomfort and pain  after treatments as measured by a 10 cm visual 
analog scale (VAS).  
• Subjects experiencing a treatment- related adverse event (AE) by [ADDRESS_674949] to participate.  
5.2 PARTICIPANT  INCLUSION CRITERIA  
1. Healthy , male or female subjects over 21 years of age  who are seeking treatment and reduction 
of their facial wrinkles . 
2. Able to read, understand and voluntarily provide written Informed Consent . 
3. Able and willing to comply with the treatment/follow -up schedule and requirements . 
4. Women of child -bearing age are required to be using a reliable method of birth control at least [ADDRESS_674950] at baseline.  
5.3 PARTICIPANT  EXCLUSION CRITERIA  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  8 1. Implantable defibrillators, cardiac pacemakers, and other metal implants  
2. Subjects with any implantable metal device in the treatment area  
3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body 
(e.g. cochlear implant).  
4. Permanent implant in the trea ted area, such as metal plates and screws, or an injected chemical 
substance.  
5. Current or history of any kind of cancer, or pre -malignant moles.  
6. Severe concurrent conditions, such as cardiac disorders.  
7. Pregnancy or intending to become pregnant during the st udy and nursing.  
8. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive  medications.  
9. History of diseases stimulated by [CONTACT_10388], such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior 
to enrollment, or according to Investigator’s discretion.  
10. Poorly controlled endocrine disorders, such as diabetes.  
11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.  
12. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.  
13. History of bleeding coagulopathies, or use of anticoagulants  (excluding daily aspi[INVESTIGATOR_248]) . 
14. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.  
15. Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topi[INVESTIGATOR_520336]; or as per physician’s discretion . 
16. Use of n on-steroidal anti- inflammatory drugs (NSAIDS, e.g. ibuprofen -containing agents) one 
week before and after each treatment session.  
17. Any surgical procedure in the treatment area within the last six months or before complete healing.  
18. Treating over tattoo or permanent makeup.  
19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.  
20. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.   
5.[ADDRESS_674951] been treated according to the study protocol .  It 
is anticipated that it will take up to eight months  to complete the study.  Subjects  will  primarily be 
recruited from the investigator’s practice .  Any advertising campaigns and materials will be reviewed 
and approved by [CONTACT_10389] I nstitution al Review Board ( EC or IRB) before implementation.  
Due to the long duration of the study, subjects will be contact[CONTACT_100956] a regular 
basis to enhance retention.  
5.[ADDRESS_674952] drops out of the study or is withdrawn from the study, the E nd of 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  9 Study /Early Discontinuation  CRF form sh ould be completed.  On the discontinuation  page , the 
Investigator should record the date of the withdrawal and the reason for withdrawal.   
Reasonable effort should be made to contact [CONTACT_100957].  The records of subjects who 
terminate prior to completing the study will be retain ed and the reason for termination will be 
documented.  
The investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in  the study would not be in the best interest of the 
subject.  
• The subject  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation.  
5.5.[ADDRESS_674953] an exit visit  (final study visit, see 
section 7.3.5)  to withdrawn patients , and to  undertake protocol -specified safety follow -up procedures 
to capture AEs, serious adverse events (SAEs) an d device deficiencies.   
5.6 PREMATURE TERMINATION OR SUSPENS ION OF STUDY  
The sponsor may suspend or prematurely terminate this study at  the investigation site for significant and 
documented reasons.  
 A principal investigator, EC/IRB, or regulatory authority may suspend or prematurely terminate 
participation in the study at the investigation site for which they are responsible.  
 
If suspi[INVESTIGATOR_10366], or when so instructed by [CONTACT_1383]/IRB or regulatory authorities, the sponsor shall suspend the clinical investigation while the risk is assessed.  
The sponsor shall terminate the study  if an unacceptable risk is confirmed.  
 
The sponsor shall consider terminating or suspending the participation of the investigation site or 
investigator in the study if monitoring or auditing identifies serious or repeated deviations on the part of 
an inve stigator.  
 If suspension or premature termination occurs, the terminating party shall justify its decision in writing 
and promptly inform the other parties with whom they are in direct communication. The principal 
investigator [INVESTIGATOR_10367] o ther informed of any communication received from either the 
EC/IRB or the regulatory authority.  
 
If, for any reason, the sponsor suspends or prematurely terminates the study at the investigation site, the 
sponsor shall inform the responsible regulatory aut hority as appropriate and ensure that the EC/IRB is 
notified, either by [CONTACT_458] [INVESTIGATOR_10368].  If the suspension or premature termination 
was in the interest of safety, the sponsor shall inform all other principal investigators.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  10  
If suspension or premature termination occurs,  
a) the sponsor shall remain responsible for providing resources to fulfil the obligations from the clinical investigative plan  and existing agreements for following up the subjects enrolled in the 
study, and  
b) the pr incipal investigator or authorized designee shall promptly inform the enrolled subjects at 
the investigation site, if appropriate  
 In case of early termination, final study activities according to the protocol, including the follow up visits and procedures to assess the safety and efficacy of the device will be conducted, regardless of the sponsor's interest in the study.  Follow -up a ctivities will be conducted so that device deficiencies can be 
identified and appr opriate safety measures can be implemented.  
 
At the completion or termination of the study, the Investigator will return all remaining clinical supplies 
to Sponsor along with  a copy of the device supply and inventory records.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  (examples of 
findings that might t rigger a safety review are the number of SAEs overall, the number of 
occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events  – 
refer to sec tion 8.5 STUDY HALTING RULES . 
• Demonstration of performance  that would warrant stoppi[INVESTIGATOR_007] 
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the sponsor, EC / IRB and/or regulatory authorities . 
6 INVESTIGATIONAL DEVICE  
 
6.1 INVESTIGATIONAL DEVIC E AND CONTROL DESCRIPTION  
 
6.1.1  ACQUISITION   
If the investigative  site does not own a Venus Viva™,  a device  will be provided  by [CONTACT_456].  An 
activation code will be required to activate the device  (not applicable if the site owns the device) .  This 
code will be pr ovided to the investigative site once  all regulatory and EC/IRB approvals are in place and 
the site has received training for both the device and the study  (if applicable) .  
6.1. 2 DEVICE SPECIFIC CONSIDERATIONS  
• Device model(s)  - Venus Viva ™  
• Device settings and programming –  Ablation and Coagulation  Mode ; 180-280 volts, 5-30 ms 
pulse duration  
• Duration of exposure and frequency –   
o For all subjects -  monthly treatment for 3 months .   
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  11 The Venus Viva ™ is a non -invasive medical aesthetic device, intended for use in dermatologic and 
general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.    
The system consists of a handheld applicator  with disposable tips.  The tip  options  include an 80 and 160 
pin  tips, 8x20 mm in size , that delivers the Multi Polar Radiofrequency (RF)  to the skin .  Further  details 
about t he Venus Viva ™ can be found  in the  device User Manual.  
6.2 INVESTIGATIONAL DEVICE  ACCOUNTABILITY PROC EDURES  
If the device is supplied by [CONTACT_456], t raceability shall be achieved during and after the clin ical 
investigation by [CONTACT_10392].   Disposal tips will be provided 
by [CONTACT_456].  
7 STUDY PROCEDURES AND  SCHEDULE  
 
7.1 STUDY PROCEDURES/EVA LUATIONS  
7.1.1  STUDY SPECIFIC  PROCEDURES   
The following procedures and evaluations will be done as part of the study : 
Demographics  
Medical /surgical history (obtained by [CONTACT_10393]/ or medical records)  
Physical examinati on 
Assessment of eligibility  
Photographs  
Histological assessment   
Blinded assessment  
Administration of questionnaires and scales for blinded reviewer and patient -reported outcomes  
Adverse event recording 
Concomitant medications  
7.2 LABORATORY PROCEDURES/EVALUATIONS    
 
7.2.[ADDRESS_674954] to be performed within 24 hours of study intervention with results available prior 
to administration of treatment.     
 For up to 12 subjects, histological samples of a separate treated  area will be obtained at baseline , 
immediate/post procedure, 2 weeks and at the final 3 month visit. 
7.2.2  OTHER ASSAYS OR PROCEDURES  
None.   
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  12  
7.3 STUDY SCHEDULE  
 
7.3.1  ENROLLMENT/ SCREENING  
 
Screening Visit  and Enrolment (Day - 7 to - 2) 
If the subject meets the preliminary study criteria , the study doctor, and/or his /her  designee, will obtain 
an informed consent from the subject  prior to any study procedure , clearly indicating his/her 
understanding of the requirements and possible risks asso ciated with study participation and other 
applicable treatment options.  Subjects will receive a unique identifying number that will be composed 
of a two -digit site number and a two -digit subject number in sequence.  This unique identifier will be 
used thr oughout the entire study and will be entered in the subject's case report form (CRF).  
During the first visit, the study investigator, and/or his /her  designee, will screen the subject for eligibility 
to participate in the clinical study using the i nclusion /exclusion criteria.  A negative urine pregnancy test 
will be obtained  (in patients of child -bearing potential) .  During screening, the study doctor will review 
the subject's medical /surgical history , demographics, physical exam  and examine the subject's targeted 
treatment area to ensure that it meets the study criteria.  The subject will complete screening and the 
treatment will be scheduled.  
Test Spots  
A small test spot will be performed in a non -conspi[INVESTIGATOR_520337], prior to the first 
complete session. Test spots are performed to establish the following requirements:  
• Confirm the patient's suitability for treatment:  
o For skin types I -III, wait 24 -48 hours  
o For skin type IV -VI, wait 5 –  7 days  before assessing the skin response  
• Establish and confirm treatment parameters:   If the desired endpoint of erythema and edema –  
in a tip -shaped pattern –  has not been achieved within [ADDRESS_674955] spot whenever changing 
parameters.   
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  13  
7.3.2  BASELINE  VISIT  
Baseline  Visit (Visit  1 – Day 0 ) 
Subjects will return to the clinic within [ADDRESS_674956] of three treatments  (see 7.3.3) .  The subject’s eligibility status at this timepoint according to the 
inclusion/exclusion criteria will be re -confirmed.  Test spot assessmen t, photographs, AEs  and any 
changes to concomitant medications will be recorded. For patients who volunteer  to receive a biopsy for 
histological assessment, a punch biopsy of an untreated area will be obtained.  This separate assessment 
area for the biopsy may be designated to a non -conspi[INVESTIGATOR_41477].  
 
7.3.3  TREATMENT VISITS  
Beginning with the Baseline visit (Visit 1 ), subjects will receive a total of 3 treatments approximately 3-5 
weeks apart .  The left and right side of the face will be treated and assessed as independent sites, and 
the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.   Adverse 
events and any changes to concomitant medications will be recorded  at these visits . 
Subjects will receive treatment as described below.   Following treatment, the investigator will examine 
the treated area and report immediate and short term response.  Subjects will complete the 10 cm 
discomfort/pain VAS and Toler ability Scale immediately after treatment.    
The investigator will examine the treated areas and report immediate and short term response ([ADDRESS_674957] -treatment) (pain during treatment, hemorrhage, burn, erythema, edema, purpura) using a 
5-point scale: 1=none; 2=trace; 3=moderate; 4=marked; 5=severe.    
The normal response to these treatments is transient erythema and edema. If any other side effects 
occur, as indicated in the protocol, th ey must be recorded.  
Visit 1 – Day [ADDRESS_674958] -treatment.   
Histology Visit – Week 1 (+/- 7 days)  
Patients who volunteer  to the Histological assessment subgroup are to return to the clinic for the Week 
1 biopsy.  A punch biops y of the separate treated area will be obtained  at this visit .  In addition to the 
biopsy, any AEs or changes to concomitant medications will be recorded.  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  14 Visit 2 – Week 4 (+/- 7 days)  
The Subject is to return to the clinic for their second of the three tr eatments.  In addition to the 
treatment, concomitant medications,  AEs and the pain VAS and Tolerability Scale are to be completed 
by [CONTACT_102].  
Visit 3 -- Week 8 (+/- 7 days)  
The Subject is to return to the clinic for their final treatment.  In addition to the treatment, concomitant 
medications,  AEs and the pain VAS and Tolerability Scale are to be completed by [CONTACT_102].  
 
Treatment  
Subjects will be asked to present to the clinic clean shaven prior to receiving treatment.  Ther e should 
be no lotion, make -up, perfume, powder, or bath/shower oil present on the skin in the area to be 
treated. Ensure that the skin is completely dry during the entire treatment. If the skin moistens during 
treatment (i.e. perspi[INVESTIGATOR_1516], etc.) re -wipe t he skin with an alcohol pad and ensure that the skin is 
completely dry before continuing the treatment.  
Depending upon the subject’s sensitivity to the test spot administration, a topi[INVESTIGATOR_520338]’s discretion.  This 
topi[INVESTIGATOR_10372].  
Set the treatment parameters  to desired treatment mode and select the appropriate tip (160 pin or 80 
pin tip) .  The selected tip will be utilized for all of the specific patient’s subsequent treatments.  Set the 
desired energy level according to the skin type, severity of the treated condition, treatment area, bone proximity, etc.  Set conservative parameters from a test spot for the first treatment, and then gradually increase during treatment or in subsequent t reatments according to the desired impact and test spot 
results.  
To perform the treatment, place the tip on the target zone, perpendicular to the skin surface and with full contact [CONTACT_8124].  Emit a pulse by [CONTACT_10394]'s trigger; this will create a tip -shaped 
pattern on the patient's skin that will appear 1 -2 minutes later. Move the applicator to an adjacent spot 
on the skin overlappi[INVESTIGATOR_10373] 10% and emit another pulse (not applicable to the test spot). There should be 
no untreated gaps betwe en the pulses.  
Examine the treated area. The immediate responses, indicative of the desired effect, are erythema and 
edema in the immediate area of the tip -shaped pattern and possibly also around it. The edema usually 
appears 1 -2 minutes after pulsing and  reaches its peak (of up to moderate edema) within 30 minutes. It 
should be noted that erythema is not easily noticeable –  if at all – in darker skin types. Therefore, the 
edema will be more prominent in these patients. After completing a full pass on the entire treatment 
area, if untreated patches of skin are apparent, re -treat these patches as per the following procedure:  
i. Wipe the untreated patch of skin with a dry gauze pad.  
ii. Treat the untreated patches of skin as normally.  
Fine -tuning of the param eters should be done before proceeding to treatment of the entire sub -area 
with the selected parameters. The applicator tip should be placed on the skin, a pulse emitted, then 
lifted and moved to an adjacent spot of the skin. The emitted pulses should crea te tip -shaped patterns. 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674959], no untreated gaps between the pattern marks, while also being careful not to overlap the treated 
zones. The parameters can be modified during subsequent visits, as per the practitioner's discretion.  
Post -Treatment Care  
Post -treatment cooling is not necessary.  In the event of post- treatment discomfort, it is recommended 
to cool the treated area immediately with air cooling.  Cold (not frozen) packs may also be used. Blistered or ulcerated skin can be treated with a prescribed cream. Tiny scabs of less than [ADDRESS_674960] -treatment and may remain for several days. The scabs 
should not be touched or scratched even if they itch, and should be allowed to shed off naturally. Blistered or ulcerated s kin can be treated with a prescribed antibiotic ointment or burn treatment cream 
as per physician's discretion.  During the first two days following treatment, care should be taken to prevent trauma to the treated site.  Hot baths, massage, etc. should be avoided. The skin should be kept 
clean to avoid contamination or infection.  Any mechanical or thermal damage to the area must be 
avoided.  Moisturizer may be applied only 24 hours after each treatment, and then should be applied regularly throughout the c ourse of the treatment.  Make- up may be applied only 24 hours after each 
treatment if desired, unless an unwanted reaction occurs in the area.  Generally, 24 hours after treatment, patients may use regular soaps, but not scrub soaps or exfoliants. The patient should use a high -factor sunscreen (at least 30 SPF) and protect the treated area from sunlight for at least one month 
after the treatment.  Tanning of any sort (sun exposure, tanning beds, and artificial sunless tanning lotions) is not allowed in the treated areas during the entire course of the treatment.  Tanning after treatment may cause hyperpi[INVESTIGATOR_371].  
Photography  
Photographs will be taken prior to first treatment and throughout the study according to specified time points detailed in the Schedule of Events Table (section 7.3.7), utilizing standard scientific equipment.     
The photos should be taken in a private ro om or area of the clinic under controlled conditions, including 
the distance, angle, background and lighting in order to achieve high -quality sets of photographs.   The 
subject should be placed in the same position each time.  As each photograph is taken, it should be viewed to ensure that it is in focus and is similar to its baseline counterpart in all technical aspects, including lighting, distance and angle.  
For consistency purposes, the same person should ideally take all study photographs, especially p er 
subject.  The digital files should follow a consistent standard naming scheme.  
7.3.4  FOLLOW UP VISITS  
Visit 4 – [ADDRESS_674961] Final Treatment (+/ - 7 days)  
Subjects will return to the clinic [ADDRESS_674962]  Satisfaction Scale and 
Treatment Evaluation Questionnaire . 
Photographs of the treated area will be taken as described in section 7.3. 3. The p hotographs will be sent 
to the blinded independent reviewer for the Fitzpatrick Winkle and Elastosis Scale (FWES) assessment .   
Visit 5 – [ADDRESS_674963] Final Treatment (+/ - 7 days)  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674964] all reportable events with start dates occurring any time after informed consent is obtained until 
7 (for non -serious AEs) or 30 days ( for SAEs) after the last day of study participation.  
7.3. [ADDRESS_674965] be completed .  
Adverse events and the reason for early termination will be recorded.  
7.3.6  UNSCHEDULED VI SIT 
If an unscheduled visit occurs, the reason for the unscheduled visit will be documented. I f the 
unscheduled visit is the result of an adverse event, the event will be recorded on the adverse event CRF.  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  17  
7.3.7  SCHEDULE OF E VENTS TABLE 
 
Procedures  
Screening Visit  
(Day -7 to - 2) 
Baseline/Treatment 1  
(Visit 1, Day 0)  
Histology Visit  
(Week 1, +/- 7 days)  
Treatment 2  
(Visit 2, Week 4 (+/ - 7 days)  
Treatment 3  
(Visit 3, Week 8 (+/ - 7 days)  
Follow -up 1  
(Visit 4, [ADDRESS_674966] -Final 
Treatment  +/- 7 days)  
Follow -up 2  
(Visit 5, [ADDRESS_674967] -Final 
Treatment +/ - 7 days))  
Informed consent  X       
Inclusion/exclusion criteria  X X      
Demographics  X       
Medical history  X       
Physical exam  X       
Concomitant medication  X X X X X X X 
Urine pregnancy test  X       
Test Spot  X (X)  (X) (X)   
Photographs   X    X X 
Administer Treatment   X  X X   
Histological Sample for Assessment   X X    X 
Adverse event evaluation   X X X X X X 
Discomfort/ Pain VAS  and Tolerability Scale   X  X X   
PI [INVESTIGATOR_484518] & short -term response   X  X X   
Subject  Satisfaction Scale       X X 
Treatment Evaluation Questionnaire       X X 
 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  
 This is a non -life-threatening aesthetic treatment  with a low potential for serious adverse events . 
7.5 CONCOMITANT MEDI CATIONS, TREATMENTS,  AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the case 
report forms (CRFs).   For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licensed clinician.  Other m edications to be reported in the CRF 
are concomitant over- the-counter medications , non-prescription me dications  and herbal/naturopathic 
preparations . 
7.6 PROHIBITED MEDICATIO NS, TREATMENTS, AND PROCEDURES  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674968] degree burn 
or pain beyond narcotics, then the following procedure will be implemented:  
• Immediate triage and treatment of the patient shall be determined by [CONTACT_41490].  
• The event will be reported to the sponsor study Director within [ADDRESS_674969] be reported on the SAE form.  
• An anonymized  copy of the patient chart and treatment parameters are to be forwarded to the 
sponsor study Director within 24 hours.   
The sponsor study Director will be responsible for issuing a written report to the company and the EC or 
IRB Chairman no later than 7 days from the event   
Long term follow up and care shall continue at the discretion of the treating physician.  
All patients experiencing a complication of the device will be followe d a minimum of 2 years following 
the initial injury.  Longer care and observation will be at the discretion of the treating physician.   
All minor complications such as appearance or altered sensation, except for pain, can be reported within 
30 days of pat ient complaint.  Both chart and treatment parameters are to be provided to the study 
Director and shared with the company and EC or IRB chairman.   
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAF ETY PARAMETERS  
In addition to spontaneous reports of adverse events, subjects will complete a 10 cm  discomfort/ pain 
VAS, Tolerability Scale and the principal investigator [INVESTIGATOR_41480].  
8.1.1  DEFINITION OF ADVER SE EVENTS  (AE)  AND ADVERSE DEVICE EFFECT (ADE)  
Adverse event means any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including  abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device . This definition includes events related to the 
investigational me dical device or the comparator.  This definition includes events rela ted to the 
procedures involved.  For users or other persons, this definitio n is restricted to events related to 
investigational medical devices  (ISO [ZIP_CODE]: 2011 ). 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674970] means any adverse event related to the use of an investigational medical device . 
This definition includes adverse events resulting from insufficient or inadequate instructions for use , 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical 
device.  This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device  (ISO [ZIP_CODE]:2011).  
8.1.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
NOTE: The term serious is not synonymous with severity, which may be used to describe the intensity of an event experienced by [CONTACT_423]).  An AE that does not meet any of the below criteria will be 
classified as non -serious.  
A serious AE  is any adverse event that:  
• led to death,  
• led to serious deterioration in the health of the subject, that either resulted in  
− a life -threatening illness or injury, or  
− a perman ent impairment of a body structure or a body function, or  
− in-patient or prolonged hospi[INVESTIGATOR_059], or  
− medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function,  
• led to fetal distress, fetal death or a congenital abnormality or birth defect  
Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_10396], without serious  
deterioration in health, is not considered a serious adverse event (ISO [ZIP_CODE]: 2011) . 
8.1.[ADDRESS_674971] ( SADE) 
This definition  include s any adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event .  Unanticipate d serious adverse device effect ( [LOCATION_003]DE ) is any 
serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome  has not been identified 
in the current version of the risk analysis report .  Anticipated serious adverse device effect (ASADE) is an 
effect which by [CONTACT_10397], incide nce, severity or outcome has been identified in the risk analysis report 
(ISO14155:2011).  
8.1.[ADDRESS_674972] to its identity, quality, durability, reliability, safety or 
performance .  Device deficiencies include malfunctions, use e rrors, and inadequate labelling (ISO 
[ZIP_CODE]:2011).  
Any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not 
been taken or b) intervention had not been made or c) if circ umstances had been less fortunate  is 
subject to  the same reporting requirement of SAEs (MEDDEV 2.7/3 revision 3).  
 
8.2 CLASSIFICATION OF AN  ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  20 For AEs not included in the protocol defined grading system, the following gu idelines will be used to 
describe severity.  
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures.  Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  
8.2.2  RELATIONSHIP TO INVESTIGATIONAL DEVICE  
The clinician’s assessment of an AE's relationship to the investigational device  is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study.  If 
there is  any doubt as to whether a clinical observation is an AE, the event should be reported.   All AEs 
must have their relationship to investigational device  assessed.  In a clinical trial, the study product must 
always be suspect. To help assess ment , the follow ing guidelines are used.  
• Not Related  – relation  to the device or procedure can be excluded  when:  
− The event is not a known side effect of the product category the device belongs to or of similar 
devices and procedures;  
− the event has no temporal relationship  with the use of the investigational device or the 
procedures;  
− the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is  biologically implausible  
− the discontinuation of medical device application or the reduction of the  level of 
activation/exposure - when clinically feasible –  and reintroduction of its use (or increase of the 
level of activation/exposure) , do not impact on the serious event;  
− the event involves a body -site or an o rgan not expected to be affected  by [CONTACT_10398];  
− the serious event can be attributed to another cause (e.g. an underlying  or concurrent illness/ 
clinical condition, an effect of another device,  drug, treatment or other risk factors) . 
• Unlikely: the relationship with the use of the device seems not relevant and/or  the event can be 
reasonably explained by [CONTACT_5748], but additional  information may be obtained.  
• Possible : the relationship with the use of the investigational device is weak but  cann ot be ruled out 
completely.  Alternative causes are also possible (e.g. an  underlying or concurrent illness/ clinical 
condition or/and an effect of another device, drug or treatment).  Cases were relatedness cannot be 
assessed or no  information has been ob tained should also be classified as possible.  
• Probable : the relationship with the use of the investigational device seems  relevant and/or the 
event cannot reasonably be explained  by [CONTACT_5748], but  additional information may be 
obtained.  
• Causal relationship : the serious event is associated with the investigational device or with 
procedures beyond reasonable doubt when:  
− the event is a known side effect of the product category the device belongs to or of similar 
devices and procedures;  
− the event ha s a temporal relationship with investigational device use/application or procedures;  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  21 − the event involves a body -site or organ that the investigational device or procedures are applied 
to or the investigational device or procedures have an effect on;  
− the ser ious event follows a known response pattern to the medical  device (if the response 
pattern is previously known);  
− the discontinuation of medical device application (or reduction of the  level of 
activation/exposure) and reintroduction of its use (or increase  of the  level of 
activation/exposure), impact on the serious event (when  clinically feasible);  
−  other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an 
effect of another device, drug or treatment) have  been adequately ruled out;  
− harm to the subject is due to error in use;  
8.2.3  EXPECTEDNESS  
Expected  (anticipated)  adverse reactions are AEs that are common and known to occur for the 
investigational device being  studied.   Expected  adverse events in this study include d iscomfort or 
significant pain post -treatment, e xcessive skin redness (erythema) and/or swelling (edema) , in-grown 
hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] (hyper - and hypo -
pi[INVESTIGATOR_371]) , scarring . Treatment of ha ir-bearing areas in males may result in some damage to the 
follicles and subsequent loss of hair.   
An AE or suspected adverse reaction is considered "unexpected"  (unanticipated) if it is not known to 
occur for the investigational device being studied and at the specificity or severity that has been 
observed  (AE not described into the Clinical protocol or User Manual).  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor.  All AEs 
including local and systemic reactions not meetin g the criteria for SAEs will be captured on the 
appropriate CRF.  Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to investigational device and study procedures (assessed only by 
[CONTACT_8703] a diagnosis), and time of resolution/stabilization of the 
event.  All AEs occurring while on study must be documented appropriately regardless of relationship. 
All AEs will be followed to adequ ate resolution.  
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be  recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed.  AEs characterized as intermittent require documentation of 
onset and duration of each ep isode.  
The PI [INVESTIGATOR_10375].  At each study visit, the investigator will inquire study subjects about the occurrence of 
AE/SAEs since the last visit. All adverse events need to be followed until r esolution or until study end, 
whichever occurs first . 
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  22  
8.4 REPORTING PROCEDURES  
 
8.4.1  ADVERSE EVENT REPORT ING  
All AEs will be recorded on the appropriate CRF and will include information about the start and stop 
dates, severi ty and relatedness.  There should be an attempt to report a “diagnosis” rather than the 
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a diagnosis should be reported only if, in the Investigator’s judgment, it is relatively ce rtain (i.e., definite 
or possible). Otherwise individual signs, symptoms and abnormal laboratory values should be reported as distinct  adverse events.  
8.4.[ADDRESS_674973] be reported to the  sponsor’s 
clinical research department immediately or within 24 hours  by [CONTACT_10399] (see contact 
[CONTACT_2212]).  
Name: [CONTACT_484543], Clinical Research Manager  
Phone: 888 -907-0115 ext. 127 
Email: [EMAIL_9329] m 
Address: [ADDRESS_674974], Toronto, Ontario, Canada, M2J 1R4  
A written report prepared by [CONTACT_079] (or designate ) must follow within seven working 
days to the clinical monitor and should include a full description of the event a nd sequence.  
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and 
submit to the study sponsor as soon as possible, but in no event later than [ADDRESS_674975].  
In accordance with the requirements of Directive 93/42/EEC, and with MEDDEV 2.7/3, the following events are considered reportable events:  
1. any SAE (whether or not study  procedure or device related),  
2. any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not been taken or b) intervention had not been made or c) if circumstances had been less fortun ate, 
3. new findings/updates in relation to already reported events.  
 The sponsor will report the above -mentioned  events to the Competent Authorities of all countries 
where the study is being conducted, within the following timelines:  
− Any SAE which indicates an imminent risk of death, serious injury, or serious illness AND that 
requires prompt remedial action for other patients/subjects, users or other persons or a new 
finding to it: immediately, but not later than 2 calendar days after awareness by [CONTACT_10400]  a 
new reportable event or of new information in relation with an already reported event.  
− Any other reportable event or a new finding / update to it: immediately, but not later than 7 calendar days following the date of awareness by [CONTACT_520342].  
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  23 Reporting of the events listed above (under bullets 1 -3) to the ECs of  the participating sites and to the 
other investigators will be performed according to country and/or site -specific  requirements.  
 
8.4. [ADDRESS_674976] or Partner Pregnancy Outcome form within  10 business days.  
8.5 STUDY HALTING RULES  
The study may be halted at any time by [CONTACT_456], the EC / IRB, Competent Authorities due  to safety 
concerns.  Examples of findings that might trigger a safety review are t he number of SAEs overall, the 
number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of 
events.   If the study is halted, the sponsor will immediately notify all investigational sites, the EC / IRB(s), 
the Competent Authorities of all countries where the study is being conducted.  
8.6 SAFETY OVERSIGHT  
Independent oversight is an important component to ensure  human subjects' protection.  Safety 
oversight will be under the direction of the sponsor and a med ical monitor.  
8.7 TRAINING REQUIREMEN TS  
Prior to patients’ enrollment, the Sponsor will provide training relevant and pertinent to the 
involvement of personnel conducting study activities. Training for investigators and staff will include study -specific protocol and CRF completion training by [CONTACT_10402] -site training on 
the use of the investigational device by [CONTACT_456].  Evidence of training will be documented during the 
site initiation visit and by [CONTACT_10403] a  device training certificate.  
[ADDRESS_674977] of  
the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s).  
• Monitoring for this study will be performed by [CONTACT_10404] . 
• On-site monitoring will occur within [ADDRESS_674978] and will occur at a 
frequency described in the Monitoring Plan.  
• Variables to be monitored will be described in the Monitoring Plan.  
• The Study Director or designate will be provided copi[INVESTIGATOR_10376] 15 business 
days of visit.  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  24  
10 STATISTICAL CONSIDER ATIONS   
 
10.1 STATISTICAL AND  ANALYTICAL PLANS  
The Statistical and Analytical Plans (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data that affect planned analyses. If revised, a formal St atistical and Analytical Plans (SAP) will be completed 
and issued prior to database lock and unblinding of the study data.   
10.2 STATISTICAL HYP OTHESES  
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• Primary Efficacy Endpoint:  
Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in facial wrinkles at [ADDRESS_674979]- treatment compared to baseline as assessed by [CONTACT_520343] (FWES).  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0) – There is an Improvement in facial wrinkles at [ADDRESS_674980]- treatment compared to baseline as assessed by [CONTACT_520344] (FWES). The efficacy 
endpoint improvement is defined as a score of > 1 on the Fitzpatrick Wrinkle and Elastosis Scale 
(FWES). This is the expected mean difference in FWES score at [ADDRESS_674981] -
treat ment assessment compared to baseline.   
 
• Secondary Efficacy Endpoint(s):  The following Null Hypotheses (H
o: µd = µpost – µpre = 0) - There is no improvement in subjects’ 
assessment of satisfaction with the treatment using a Subject Satisfaction Scale at [ADDRESS_674982] -treatment.  
 The following Alternative Hypotheses (H
a: µd = µpost – µpre  ≠ 0) - There is an improvement in 
subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale at [ADDRESS_674983]- treatm ent. 
 
• Safety Endpoint:  
Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no difference in subjects’ 10 cm discomfort/pain 
VAS score and Tolerability Scale experienced at Visit 4 treatment compared to that which was 
experienced at baseline treatment (Visit 2).  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0) – There is a difference in subjects’ 10 cm 
discomfort/pain VAS score and Tolerability Scale experienced at Visit 4 treatment compared to that which was experienced at baseline treatment (Visit 2).  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  25  
10.3 ANALYSIS DATASE TS 
Modified Intention -to-Treat Analysis Dataset will be used; Efficacy and safety analyses will be carried out 
on all subjects who received at least one treatment of Venus Viva™ fractional RF device and for whom at 
least one valid post -baseline efficacy and s afety evaluation were obtained.  
10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1 GENERAL APPROACH  
This is a prospective, single center, evaluator- blind study of the safety and performance of fractional 
radiofrequency (RF) for the treatment and reduction of  facial wrinkles.  
All summary tables for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant). All summary tables for qualitative parameters will display counts, percentages and number of missing data if relevant. Baseline data are defined as the last measurement, photograph or assessment performed before the first treatment on Visit 2.  
All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used to compare the evaluations at the baseline and post treatment session s. 
This test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to determine the efficacy of the treatment.  
In other to accommodate imbalances of some baseline FWES scores,  covariate adjustment analysis may 
be performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The assumption for the statistical test is that the paired differences of baseline and post treatment data  
are normally distributed  
10.4.2 ANALYSIS OF T HE PRIMARY EFFICACY ENDPOINT(S)  
The following will be considered for the analysis primary endpoint:  
Summary table for differences of baseline compared to [ADDRESS_674984] error.  The 
Fitzpatrick Wrinkle and Elastosis Scale (FWES) is a 9 -level ordinal scale tool for assessing reduction of facial 
wrinkles.  
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  26 Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Fitzpatrick Wrinkle 
and Elastosis Scale (FWES).  
 All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Wh ere appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used to compare the evaluations between baseline and [ADDRESS_674985] treatment assessments. Analysis of Covariance (ANCOVA) may also be u sed 
where appropriate. Since the primary endpoint is based on achieving a fixed scale point on the FWES, covariate adjustment analysis may be performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis in covariate adjustment analysis may be performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The Paired t -test and/or Wilcoxon Signed -Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypo theses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further s tatistical test tools such as Confidence Interval and/or t -test 
will be used to test expected primary endpoint; that is alternative hypothesis that Ha > 1. This will be used 
to determine if the study meets the primary endpoint; FWES score of > 1. 
FWES scor es of all subjects who received at least one treatment of Venus Viva™ fractional RF device and 
for whom at least one valid post -baseline FWES assessment were obtained will be analyzed for the 
primary endpoint. Multiple imputation method or modelling of available data may be used for missing data as appropriate . 
10.4.3 ANALYSIS OF T HE SECONDARY ENDPOIN T(S)  
For the analysis of secondary endpoints, the following analysis will be considered:  
Summary tables for differences of baseline compared to [ADDRESS_674986]-
treatment of subjects’ assessment of satisfaction with the treatment using a Subject  Satisfaction Scale  will 
be displayed as mean difference, standard deviation and standard error.  The point level for each of these ordinal scale assessment tools will be put into consideration where applicable.  
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages or proportions of Subjects’ assessment of satisfaction with the treatment us ing a Subject  Satisfaction Scale  
will be used to analyse efficacy.  
 All statistical tests that will be one -sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks 
Test for Matched Pairs will be used to compare the evaluations score differences of baseline compared to 
6-week and baseline compared to [ADDRESS_674987] treatment assessment. Analysis of Covariance (ANCOVA) 
may also be used whe re appropriate.  
Subjects’ assessment of satisfaction with the treatment using a Subject  Satisfaction Scale of all subjects 
who received at least one treatment of Venus Viva™ fractional RF device and for whom at least one valid 
post -baseline assessment was  obtained will be analysed for these secondary endpoints. Multiple 
imputation method or modelling of available data may be used for missing data as appropriate.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  27 10.4.4 SAFETY ANALYS ES 
The safety analysis will be done by [CONTACT_520345] (AE), subjects 
completed 10 cm discomfort/pain VAS and Tolerability Scale as well as analysis of immediate and short 
term response reports by [CONTACT_458] [INVESTIGATOR_10377]/her observation/examination of the treated area. Appropriate Medic al Dictionary for Regulatory Activities (MedDRA) code will be used to describe all 
spontaneously reported or other study related adverse events.  
Summaries of spontaneously reported or other study related adverse events will be presented as:  
o Number (%) of s ubjects with any AE,  
o Number (%) of subjects with any serious adverse events (SAE),  
o Number (%) of subjects permanently withdrawn from treatment due to AE  
Summaries of analysis of immediate and short -term response reports by [CONTACT_458] 
[INVESTIGATOR_520339] a bar or pie chart as;  
o the overall frequency of subjects with each event (pain during treatment, hemorrhage, burn, erythema, edema, purpura)  
o Frequency of subjects with specific severity/intensity for each event using a 5 points s cale: 
1=none; 2=trace; 3=moderate; 4=marked; 5=severe  
o The overall percentage or proportion of subject observed with marked or severe intensity of any event will be calculated and compared to those with none, trace or moderate severity/intensity with the ai d of a bar or pie chart.  
The following will be considered for the analysis of 10 cm discomfort/pain VAS scores safety data:  
Summary table for differences of baseline and Visit 4 treatment 10 cm discomfort/pain VAS scores will be 
displayed as mean differenc e, standard deviation and standard error.  The 10 cm discomfort/pain VAS  is 
a 11 -level  (0 to 10) ordinal scale tool for assessing pain.  
 
Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Visit 4 treatment 
and baseline  (Visit 2) VAS scores difference and Tolerability Scale will be used to analyse subjects’ 
tolerability of this treatment.  
 
All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all te sts of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used to compare the difference between baseline and Visit [ADDRESS_674988] and/or Wilcoxon Signed -Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to test expected safety endpoint; that is alternative hypothesis, H a < 1.  
10.4.5 ADHER ENCE AND RETENTION A NALYSES  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  28 Adherence to the protocol will be assessed by [CONTACT_10408] (%) subjects’ data for each endpoint 
assessment that is not provided in subjects Case Report Forms. This will be further analysed as per frequency of each endp oint data that is not available due to loss to follow -up, discontinuation of the 
intervention or any other reason.  
 
10.4.6  BASELINE DES CRIPTIVE STATISTICS  
Subjects baseline scores of all endpoints (FWES, Subject Satisfaction Scale, Treatment Evaluation 
Questionnaire , VAS and Tolerability Scale) will be compared using descriptive statistics such as mean 
score, standard deviation, standard error, range and graphical presentations.  
10.4.7 PLANNED INTER IM ANALYSES  
N/A - There will be no interim analysis du ring this study.  
 
[IP_ADDRESS]  SAFETY REVIEW  
There will be no interim analysis during this study. However, this study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause as per section 5.5 and 8.5.  
[IP_ADDRESS]  EFFICACY REVIEW  
There will be no interim analysis during this study. However, this study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause as per section 5.5 and 8.5.  
10.4.8  ADDITIONAL SU B-GROUP ANALYSES 
Not Applicable -  Primary or secondary endpoint will not be analyzed based on age, sex, race/ethnicity or 
other demographic characteristic(s).  
10.4.9 MULTIPLE COMP ARISON/MULTIPLICITY  
Not Applicable   
10.4.10  TABULATION O F INDIVIDUAL RESPONSE DATA  
Individual participant data will be listed by [CONTACT_10409].  
10.4.11  EXPLORATORY ANALYSES 
Not Applicable   
10.5 SAMPLE SIZE  
The primary and safety endpoints outcome measures were used to calculate the study sample size.  
Sample size calcu lation using primary endpoint outcome measure;  
• Null and alternate hypotheses:  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  29 o Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in facial wrinkles at [ADDRESS_674989]- treatment compared to baseline as assessed by [CONTACT_10410] 
(FWES).  
 
o Alternative Hypothesis (Ha: µd = µpost – µpre ≠ 0) – There is an Improvement in facial 
wrinkles at [ADDRESS_674990]- treatment compared to baseline as assessed by 
[CONTACT_520346] (FWES). The efficacy en dpoint improvement is defined as a score of >  1 on 
the Fitzpatrick Wrinkle and Elastosis Scale (FWES). This is the expected mean difference  
in FWES score at [ADDRESS_674991]- treatment assessment compared to baseline.  
• In view of the nature of this st udy in regard to treatment and follow -up duration, we make 
provision for 20 % study drop out, withdrawal or loss to follow -up. 
• 1- Tailed Sample Size calculation formula for Matched Samples was used in the table below:  
 
(1-β), Power  0.8 
α, Level of Significance  0.05  
μd, mean difference; this is the smallest possible change 
expected under H a [ADDRESS_674992] Deviation of the difference scores (FEW 
Scale range ÷ 4) = [(9 -1)÷4]  2 
Z1-α/2 1.645 
Z1-β, (for 90%)  0.84  
Estimated Sample Size   25 
Estimated Sample Size + 20% drop out  ~30 
Conclusion: The estimated sample size for treatment sites and the additional 20% provision for drop out 
(30 treatment sites)  obtained from the primary endpoint outcome measure calculation will be used 
subjects for this study. 1 5 subjects will unde rgo treatment on 2 different sites; one on each side of the 
face that will be will be assessed independently as two separate sites.  
10.6 MEASURES TO MINI MIZE BIAS  
 
10.6.1 ENROLLMENT/ RANDOMIZATION/ MASKIN G PROCEDURES  
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. The subject number will cons ist of a two -digit code corresponding 
to the site and a two -digit subject code in numerical sequence. (Example: 10 -05 corresponds to site #10, 
subject #5.)  
10.6.2 EVALUATION OF SUCCESS OF BLINDING   
NA - All subjects will receive treatment.   
10.6.3 BREAKING THE STUDY B LIND/PARTICIPANT COD E 
N/A - All subjects will receive treatment.     
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  30 11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ISO [ZIP_CODE]:2011 , and regulatory and institutional requirements for the protection of 
confidentiality of participants. Each site will permit authorized representatives of the study sponsor , 
ethic s committee and/or regulatory agencies to examine (and whe n permitted by [CONTACT_1289], to 
copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study 
safety, progress, and data validity.  
Source data are all information, original records of clinical findings, observ ations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory no tes, memoranda, participants' memory aids or evaluation checklists, pharmacy dispensing 
records, recorded audio tapes of counseling sessions, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives  (where  applicable) , microfilm or magnetic media, x -rays, and participant files 
and records kept at the pharmacy, at the laboratories, and medico -technical departments involved in 
the clinical trial.  
It is acceptable to use CRFs as source documents.  The following CRFs collected on no carbon required 
(NCR) paper will be source documents:  
• Subject self -reported VAS and Tolerability  Scale, FWES and Subject  Satisfaction Scale  
The remainder of the data  collected  from other sources.  
It is no t acceptable for the CRF to  be the only record of a subject’s  participation in the study. This is to 
ensure that anyone who would access the patient medical record has adequate knowledge that the 
patient is participating in a c linical trial.  
12 QUALITY ASSURANCE AN D QUALITY CONTROL  
Prior to any independent use of the Venus Viva ™ device, study personnel, will receive proper training 
from the sponsor. Site personnel will be trained on the use of the device prior to study initiatio n at the 
site.  Additional  training requirements will be discussed during study initiation and will include site 
responsibilities, and study documentation.  In addition, the sponsor will provide protocol specific training 
for the site. The site will document which individual has been assigned to a specific task and will ensure that appropriate training has occurred for that task.  
Regular monitoring and an ind ependent audit, if conducted, must be performed according t o ISO 
[ZIP_CODE]:2011. See also Section 9, Clinical Monitoring.  
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the databa se will be generated.  Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
Monitors will verify that the clinical trial is conducted,  and data are generated, documented (recorded), 
and reported in compliance  with the protocol, GCP, and the applicable regulatory requirements.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674993] access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspectio n by [CONTACT_10412].  
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.[ADDRESS_674994] version of the 
Declaration of Helsinki (2013), ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human 
subjects - Good clinical practice) , FDA and any other applicable country’s  ethical policy statement, 
whichever provides the higher level of protection to human subjects.  
13.2 ETHICS COMMITTEE AND COMPETENT AUTHORITIES  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the EC  / IRB  for review and approval. Approval of both the protocol and the consent form 
must be obtained before an y participant is enrolled. Any amendment to the protocol will require review 
and approval by [CONTACT_1383] / IRB before the changes are implemented to the study. All changes to the 
consent form will be EC  / IRB approved; a determination will be made by [CONTACT_520347] -consented.  
13.3 INFORMED CONSENT PROCESS  
 
13.3.1  CONSENT/ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed 
consent, the investigator should comply with applicable regulatory requirements and should adhere to 
ISO [ZIP_CODE]:[ADDRESS_674995] version of the Declaration of Helsinki (2013) .  Prior to th e beginning of 
a trial, t he investigator should have the EC / IRB's written approval for the protocol and the written 
informed consent  forms(s) and any other written information to be provided to the participants.  
Consent forms describing in detail the investigational medical device , study procedures, and risks are 
given to the participant and written documentation of informed consent is required prior to starting 
intervention  with  investigational medical device . 
13.3.2  CONSENT PROCEDURES AND DOCUMENTATION  
Informed consent is a  process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participan ts and their families.   Consent forms 
will be EC or IRB approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the participant and answer any questions that may arise. All participant s will receive a verbal explanation in terms suited to their comprehension of the purposes, 
procedures, potential risks of the study and their rights as research participants.   Participants will have 
the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates or think about it 
prior to agreeing to participate.  The participant will sign the informed consent document prior to any 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674996] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents . This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No 
information concerning the study or the data will be released to any unauthorized third party without 
prior written approval of the sponsor.  
The study mo nitor, other authorized representatives of the sponsor, representatives of the EC / IRB and  
Competent Authorities or device  company supplying study product may inspect all documents and 
records required to be maintained by [CONTACT_093], including but n ot limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site 
will permit access to such records.  
The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_456],  and any applicable regulations  (refer to section 14.2 STUDY 
RECORDS RETENTION ). 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the sponsor’s office . This will not include the participant’s contact [CONTACT_10415]. Rather, indiv idual participants and their research data will be identified by a 
unique study identification number. The study data entry and study management systems used by [CONTACT_100977]’s research staff will be secured and password protected.  At the end of the 
study, all study databases will be de -identified and archived by  [CONTACT_456] . 
13.4.[ADDRESS_674997] -treatment changes in  skin morphology .  
Access to stored samples will be limited to the principal investigator’s staff or designated lab and will be 
stored securely. Only investigators will have access to  the samples. The sponsor will not have access to 
the samples, only the data generated from the samples.  
Disposition at the completion of the study: The investigator will store all the samples u pto [ADDRESS_674998] and all supporting details will be maintained for tracking.  
13.5 FUTURE USE OF STORED  SPECIMENS  
The histo logical  samples will not be used for any other research other than this stud y. 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_674999] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIB ILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
Principal Investigator.  The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.  Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or 
corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT 
ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_10380].   Data reported in the CRF derived from source documents 
should be consistent with the source documents or the discrepancies should be explained and captu red 
in a progress note and maintained in the participant’s official study record.   Self-reported subject data  
and investigator CRF reported data recorded on the copy CRF page is permitted.  The original form will 
be collected by [CONTACT_520348].  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data from paper CRFs will be entered directly onto paper CRFs from the source documents 
and will be collected by [CONTACT_4530].  
14.2 STUDY RECORDS RETENT ION  
Study documents , including copi[INVESTIGATOR_10381], signed informed consent forms, photographs  
(where  applicable) , laboratory results, medical records , data clarification forms  and regulatory 
documents,  should be retained for a minimum period of 5 years after the end of the clinical 
investigation, or longer if required by [CONTACT_1295]. The investigator should take measures to prevent 
accidental or early destruction of the study related materials .  No records will be destroyed without the 
written consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 
investigator when these documents no longer need to be retained.  
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is any instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the Clinical Investigation Plan.  Applicable definition follow:  
− Major deviation: CIP deviations that can have affected the rights, safety or well- being of the subjec t 
or the scientific integrity of the clinical investigation.  
− Minor deviation: CIP deviations that do NOT have affected the rights, safety or well- being of the 
subject or the scientific integrity of the clinical investigation.  
The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ISO [ZIP_CODE]:2011: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, 2018 
  34 • 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_675000] been met:  
a. The Investigator, the Sponsor and Statistician have approved the protocol amendment and  
b. The responsibl e EC and Competent Authority has reviewed an d approved the protocol change.  
Under emergency circumstances, deviations from the CIP to protect the rights, safety and well -being of 
human subjects may proceed without prior approval of the sponsor and the EC.  Such deviations shall be 
documented and reported to the sponsor and the EC as soon as possible.  
A corrective action will be taken: documenting the deviation (source document, log, CRF as relevant) 
including its reasons of occurrence and corrective actions to be taken to further avoid reoccurrence of it 
and properly reporting. The investigator as well as site personnel will be trained in order to avoid any 
major protocol deviation in the future.  
Failure to comply with this clinical investigation plan  and/or EC, Competent Authorities, any local 
requirement will result in corrective actions and could result in the removal of the investigator from the 
study.  
It is the responsibility of the site to use continuous vigilance to identify and report deviation s promptly 
to study sponsor and to EC (if required by [CONTACT_1295] ).  All deviations must be addressed in study 
source documents.  The site PI/study staff is responsible for knowing and adhering to their EC 
requirements .  
14.4 PUBLICATION AND DAT A SHAR ING POLICY  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assig ns human subjects to intervention or concurrent comparison or 
control groups to study the cause -and-effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treat ments, 
process -of-care changes, and the like.  Health outcomes include any biomedical or health -related 
measures obtained in patients or participants and adverse events. The ICMJE policy, and the  Section [ADDRESS_675001] of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_10418]. Other biomedical journals are considering adopting similar policies.  The Decla ration of 
Helsinki current revision (2013) states that every research study involving human subjects must be 
registered in a publicly accessible database before recruitment of the first subject (sec.35).  
The sponsor or its designee  will register the
 VI1218  study into a publicly accessible database .  All data 
generated from this study are the property of Venus Concept Ltd and shall be held in strict confidence 
along with all information furnished by [CONTACT_10419] . 
Independent analysis and/or publication o f these data by [CONTACT_10420]/her 
staff are not permitted without prior written consent of Venus Concept Ltd.   Written permission to the 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_675002].  
17  LITERATURE REFERENCES  
1. George Hruza, Amy Forman Taub, Susannah L. Collier, Stephen Robert Mulholland . Skin 
rejuvenation and wrinkle reduction using a fractional radiofrequency system.  J Drugs  Dermatol. 
2009 Mar; 8(3): 259– 265. 
2. Ruiz- Esparza J, Gomez JB. The medical face lift: a noninvasive, nonsurgical approach to tissue 
tightening in facial skin using nonablative radiofrequency. Dermatol Surg. 2003;29(4):[ADDRESS_675003] D, Bernstein E, et al. Histological and ultrastructural evaluation of the effects of a 
radiofrequency -based nonablative dermal remodeling device: a pi[INVESTIGATOR_799]. Arch Dermatol. 
2004;140(2):204- 209.  
4. Drew PJ, Watkins A, McGregor AD, Kiernan MN, Clem ent M. The effects of temperature and time 
on thermal bond strength in tendons. Lasers Med Sci. 2001;16(4):291 -298.  
5. Alster TS, Lupton JR. Nonablative cutaneous remodeling using radiofrequency devices. Clin Dermatol. 2007; 25:487 -491.  
6. de Felipe I, Del Cueto  SR, Pérez E, Redondo P. Adverse reactions after nonablative radiofrequency: 
follow -up of 290 patients. J Cosmet Dermatol. 2007;6(3):163- 166.  
7. Gold MH, Goldman MP, Rao J, Carcamo AS, Ehrlich M. Treatment of wrinkles and elastosis using 
vacuum -assisted bipol ar radiofrequency heating of the dermis. Dermatol Surg. 2007;33(3):300 -309.  
8. Royo de la Torre J, Moreno -Moraga J, Muñoz E, Cornejo Navarro P. Multisource, Phase -controlled 
Radiofrequency for Treatment of Skin Laxity: Correlation Between Clinical and In -vivo Confocal 
Microscopy Results and Real -Time Thermal Changes. J Clin Aesthet Dermatol. 2011;4(1):28 -35. 
9. Alexiades -Armenakas M, Dover JS, Arndt KA. Unipolar versus bipolar radiofrequency treatment of 
rhytides and laxity using a mobile painless delivery method . Lasers Surg Med. 2008;40(7):446 -453.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Facial 
Wrinkles  Version 1.0 
Protocol # VI1218  October 9, [ADDRESS_675004]  
ISO [ZIP_CODE]:2011  International Organization for Standardization Good Clinical Practices for Clinical 
Investigations of Medical Devices  
MedDRA  Medical Dictionary for Regulatory Activities  
PI [INVESTIGATOR_10382]  
 